[go: up one dir, main page]

MA33412B1 - Compositions adjuvantes contenant un agent d'isotonicité non ionique - Google Patents

Compositions adjuvantes contenant un agent d'isotonicité non ionique

Info

Publication number
MA33412B1
MA33412B1 MA34506A MA34506A MA33412B1 MA 33412 B1 MA33412 B1 MA 33412B1 MA 34506 A MA34506 A MA 34506A MA 34506 A MA34506 A MA 34506A MA 33412 B1 MA33412 B1 MA 33412B1
Authority
MA
Morocco
Prior art keywords
isotonicity agent
compositions containing
adjuvant compositions
ionic isotonicity
ionic
Prior art date
Application number
MA34506A
Other languages
Arabic (ar)
English (en)
Inventor
Veronique Henderickx
Dominique Ingrid Lemoine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33412(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA33412B1 publication Critical patent/MA33412B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions adjuvantes et immunogènes renfermant un agoniste du TLR-4 et une saponine dans une formulation liposomique et un agent d'isotonicité non ionique, la concentration en chlorure de sodium ou la force ionique étant inférieure à 100 mM.
MA34506A 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique MA33412B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (fr) 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique

Publications (1)

Publication Number Publication Date
MA33412B1 true MA33412B1 (fr) 2012-07-03

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34506A MA33412B1 (fr) 2009-06-10 2010-06-08 Compositions adjuvantes contenant un agent d'isotonicité non ionique

Country Status (31)

Country Link
US (2) US20120087976A1 (fr)
EP (1) EP2440242B1 (fr)
JP (3) JP5647677B2 (fr)
KR (1) KR101473686B1 (fr)
CN (2) CN104367997B (fr)
AU (1) AU2010257538B2 (fr)
BR (1) BRPI1012890B1 (fr)
CA (1) CA2764421C (fr)
CL (1) CL2011003113A1 (fr)
CO (1) CO6440528A2 (fr)
CY (1) CY1115522T1 (fr)
DK (1) DK2440242T3 (fr)
DO (1) DOP2011000346A (fr)
EA (1) EA024074B1 (fr)
ES (1) ES2494442T3 (fr)
GB (1) GB0910046D0 (fr)
HR (1) HRP20140792T1 (fr)
IL (1) IL216231A0 (fr)
MA (1) MA33412B1 (fr)
MX (1) MX2011013162A (fr)
MY (1) MY159819A (fr)
NZ (1) NZ596503A (fr)
PE (1) PE20120319A1 (fr)
PL (1) PL2440242T3 (fr)
PT (1) PT2440242E (fr)
RS (1) RS53550B1 (fr)
SG (1) SG176638A1 (fr)
SI (1) SI2440242T1 (fr)
SM (1) SMT201400134B (fr)
UA (1) UA104888C2 (fr)
WO (1) WO2010142685A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58855B1 (sr) 2009-06-10 2019-07-31 Chugai Pharmaceutical Co Ltd Tetraciklična jedinjenja
JP4918630B1 (ja) 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
EP3023106B1 (fr) 2010-12-14 2019-07-31 GlaxoSmithKline Biologicals S.A. Compositions antigéniques de mycobacterium
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
CN107124869B (zh) * 2014-03-25 2022-04-01 美国政府陆军部 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CA2973857C (fr) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Medicament d'association
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
WO2018104313A1 (fr) * 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Nouveau procédé
JP2020521781A (ja) 2017-05-30 2020-07-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リポソームに内包されたｒｎａを製造する方法
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN111670044A (zh) * 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
MX2020005480A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Extraccion de saponina.
IL281079B2 (en) 2018-09-04 2024-12-01 Chugai Pharmaceutical Co Ltd Method of producing a tetracyclic compound
WO2020109365A1 (fr) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
WO2021023692A1 (fr) * 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Procédé de préparation d'une composition comprenant un polypeptide de protéine d
WO2021038508A1 (fr) 2019-08-30 2021-03-04 Glaxosmithkline Biologicals Sa Procédé de fabrication de nanoparticules lipidiques mélangées par jet
JP7599258B1 (ja) * 2023-03-15 2024-12-13 ユナイテッド・イミュニティ株式会社 脂質粒子
WO2025180443A1 (fr) * 2024-02-29 2025-09-04 Immunadd Inc. Composition d'adjuvant, composition pharmaceutique la comprenant, et méthode de prévention ou de traitement d'une maladie provoquée par une infection virale, une infection bactérienne, une infection protozoaire ou un cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DK1584685T3 (da) 1998-02-05 2011-07-11 Glaxosmithkline Biolog Sa Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
HU225844B1 (en) * 1998-05-07 2007-10-29 Corixa Corp Adjuvant composition and its use
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP2008521385A (ja) * 2004-11-29 2008-06-26 長春華普生物技術有限公司 アジュバントとしてのＣｐＧ含有一本鎖デオキシヌクレオチド
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL2114993T3 (pl) 2007-01-15 2013-01-31 Glaxosmithkline Biologicals Sa Szczepionka
WO2008089074A2 (fr) 2007-01-15 2008-07-24 Glaxosmithkline Biologicals Sa Protéine hybride
MX2009012381A (es) * 2007-05-24 2009-12-01 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada.
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
EA201190286A1 (ru) 2012-06-29
CN104367997B (zh) 2019-01-22
ES2494442T3 (es) 2014-09-15
MY159819A (en) 2017-02-15
SMT201400134B (it) 2014-11-10
EP2440242A1 (fr) 2012-04-18
US20180021417A1 (en) 2018-01-25
JP6261647B2 (ja) 2018-01-17
PE20120319A1 (es) 2012-04-16
EA024074B1 (ru) 2016-08-31
NZ596503A (en) 2013-08-30
JP5647677B2 (ja) 2015-01-07
HRP20140792T1 (hr) 2014-10-10
US20120087976A1 (en) 2012-04-12
EP2440242B1 (fr) 2014-06-25
CN102458457A (zh) 2012-05-16
DOP2011000346A (es) 2012-01-15
CY1115522T1 (el) 2017-01-04
SI2440242T1 (sl) 2014-09-30
JP2016193912A (ja) 2016-11-17
CA2764421A1 (fr) 2010-12-16
CO6440528A2 (es) 2012-05-15
WO2010142685A1 (fr) 2010-12-16
CN104367997A (zh) 2015-02-25
JP5977789B2 (ja) 2016-08-24
AU2010257538A1 (en) 2011-12-08
MX2011013162A (es) 2012-01-30
KR101473686B1 (ko) 2014-12-18
GB0910046D0 (en) 2009-07-22
PL2440242T3 (pl) 2014-11-28
RS53550B1 (sr) 2015-02-27
PT2440242E (pt) 2014-08-29
CN102458457B (zh) 2015-05-20
UA104888C2 (uk) 2014-03-25
IL216231A0 (en) 2012-01-31
KR20120031497A (ko) 2012-04-03
CL2011003113A1 (es) 2012-08-31
AU2010257538B2 (en) 2016-10-20
SG176638A1 (en) 2012-01-30
DK2440242T3 (da) 2014-09-01
JP2015042646A (ja) 2015-03-05
JP2012529464A (ja) 2012-11-22
BRPI1012890B1 (pt) 2022-03-22
BRPI1012890A2 (pt) 2018-02-27
CA2764421C (fr) 2016-12-06

Similar Documents

Publication Publication Date Title
MA33412B1 (fr) Compositions adjuvantes contenant un agent d'isotonicité non ionique
MX2007007305A (es) Composiciones para limpiar la piel que se retiran por enjuague o con un pano.
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
EP2019857A4 (fr) Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunite cellulaire
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
MX2007003078A (es) Compuestos de imidazoquinolina.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30624B1 (fr) Vaccin anti-grippal
NO20064584L (no) Tetrahydropyridoindolderivater
MY149911A (en) Methods for administering long-lasting hypoglycemic agents
MA32018B1 (fr) Vaccin
JP2016166248A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
MA35158B1 (fr) Formulations topiques de type suspension comprenant un depsipeptide cyclique
MA30711B1 (fr) Sels d'ethers benzimidazolyle pyridyle et formulations associees
TW200616647A (en) Progression inhibitor for disease attributed to abnormal accumulation of liver fat
MX2010002773A (es) Antigenos mutantes de gas57 y anticuerpos de gas57.
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
JP2018193403A (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
JP5528126B2 (ja) Ｔｒｐａ１の活性抑制剤および活性抑制方法ならびに皮膚外用剤
JP2010043047A5 (fr)
CL2009000390A1 (es) Composicion liquida de limpieza que comprende 1-30% en surfactante anionico, hasta 5% en surfactante anfotero, 2% de electrolito, 5% de surfactante monoalcanolamida y entre 50-94,5% de agua; kit; uso.
MA30489B1 (fr) Compositions nasale et buccale pour lutter contre le ronflement
BRPI0415576A (pt) composição para cuidados pessoais contendo um tensoativo detersivo, um componente anticaspa e tensoativos de cetoamida